SCHEMBL5535527

SCHEMBL5535527

COc1ccc(-c2cccc3s[c]nc23)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
ABCB1 P08183 1/20 0.42
BCR P11274 1/20 0.42
ENPP1 P22413 2/20 0.42
ENPP3 O14638 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.40
PKM P14618 1/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
PTGS2 P35354 2/20 0.40
APP P05067 1/20 0.40
CRHR1 P34998 1/20 0.39
BACE1 P56817 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
ACACA Q13085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4337978 0.82 LIMK1 (0.39) ENPP1BACE1ALDH1A1HPGDMAPK1
SCHEMBL5542129 0.81 L3MBTL1 (0.43) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL10411212 0.78
SCHEMBL16150637 0.78 NOTUM (0.38) NPC1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL5544603 0.76 ACACA (0.44) ABL1ABCB1BCRNPC1RAB9A
SCHEMBL558137 0.74 ALDH1A1 (0.49) NPC1RAB9ASMN1; SMN2KDM4EPKM
SCHEMBL20895126 0.71 ABL1 (0.44) ABL1ABCB1BCRENPP1ENPP3
SCHEMBL5506887 0.70 ADORA1 (0.36) ENPP1PTGS2
SCHEMBL21351983 0.69
SCHEMBL5540744 0.69 ABL1 (0.44) ABL1ABCB1BCRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ABL1 2364/4885ABCB1 2408/4885BCR 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.